Gene Therapy Bioassays Market Report 2026

The gene therapy bioassays market size has grown rapidly in recent years. It will grow from $1.21 billion in 2025 to $1.41 billion in 2026 at a compound annual growth rate (CAGR) of 16.5%. The growth in the historic period can be attributed to growth in gene therapy research programs, expansion of viral vector manufacturing, increasing clinical trial activity, adoption of standardized bioassay protocols, rising regulatory scrutiny on gene therapy products.

The gene therapy bioassays market size is expected to see rapid growth in the next few years. It will grow to $2.62 billion in 2030 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to increasing commercialization of gene therapies, rising demand for high-throughput bioassay solutions, expansion of personalized genetic medicine, growing investments in advanced cell and gene therapy pipelines, increasing focus on assay automation and reproducibility. Major trends in the forecast period include increasing adoption of cell-based potency assays, rising demand for viral vector characterization tests, growing use of automated bioassay platforms, expansion of regulatory-compliant assay validation, enhanced focus on functional gene expression analysis.

The rising number of gene therapy clinical trials is expected to drive growth in the gene therapy bioassays market. Gene therapy clinical trials assess the safety, efficacy, and biological performance of gene-based treatments in human subjects. The expansion of these trials is driven by intensified research and development activities and growing investments from biopharmaceutical companies aiming to address unmet medical needs through innovative genetic therapies. Gene therapy bioassays support clinical development by providing essential analytical tests to evaluate biological activity, potency, safety, and mechanisms of action at each stage of development, with regulatory requirements becoming more stringent as programs advance through clinical phases. For instance, in January 2026, according to the Bioindustry Association (BIA), a UK-based national trade association, the UK had 193 ongoing advanced therapy clinical trials, with more than 80% focused on gene therapies. Therefore, the increase in gene therapy clinical trials is driving the growth of the gene therapy bioassays market.

Leading companies operating in the gene therapy bioassays market are focusing on integrating artificial intelligence and machine learning into bioassay analysis, such as AI-enabled digital PCR data interpretation, to improve accuracy, reduce experimental variability, accelerate result turnaround times, and optimize the evaluation of therapeutic efficacy and safety in gene therapy development. AI-enabled dPCR data interpretation uses advanced algorithms to automate result analysis, distinguish true signals from background noise, and accurately quantify viral genomes or vector copy numbers with minimal human intervention. For example, in April 2025, QIAGEN N.V., a Germany-based molecular diagnostics company, launched expanded QIAcuity lentivirus solutions, including the QIAcuity RCL Quant Kit and CGT dPCR assays. These solutions incorporate algorithm-driven absolute quantification, multiplex and singleplex assay compatibility for vector genome and vector copy number analysis, and software-assisted data analysis workflows designed to support regulatory-compliant decision-making in gene therapy bioassay applications.

In April 2025, Artis BioSolutions LLC, a US-based cell and gene therapy contract development and manufacturing company, acquired Landmark Bio for an undisclosed amount. With this acquisition, Artis BioSolutions aims to broaden its service portfolio and strengthen its end-to-end capabilities across gene therapy production, including advanced manufacturing and analytical support increasingly required by biopharmaceutical companies in the gene therapy and bioassay market. Landmark Bio PBLLC is a US-based contract development and manufacturing organization (CDMO) that provides gene therapy bioassays, delivering analytical and quality control testing to support the safety, potency, and efficacy evaluation of cell and gene therapy products.

Major companies operating in the gene therapy bioassays market are Boehringer Ingelheim BioXcellence, AGC Biologics, ICON plc, Lonza Group AG, SGS SA, Eurofins Scientific SE, WuXi AppTec, Charles River Laboratories International Inc., Catalent Inc, Recipharm AB, KBI Biopharma, Syngene International Limited, QPS Holdings LLC, BioAgilytix Labs (operationally independent CRO), Oxford Biomedica plc, Viralgen Vector S.L., ProtaGene Inc., Center for Breakthrough Medicines, RoslinCT, Immunologix Labs, Genezen Laboratories.

Tariffs are impacting the gene therapy bioassays market by increasing costs of imported laboratory reagents, cell lines, analytical instruments, and specialized consumables used in assay development and quality control. Biotechnology and pharmaceutical companies in North America and Europe are most affected due to reliance on global reagent supply chains, while Asia-Pacific faces higher costs for assay equipment imports. These tariffs are increasing operational expenses and slowing assay scale-up activities. However, they are also encouraging regional reagent manufacturing, localized assay development services, and long-term investment in domestic life science infrastructure.

The gene therapy bioassays market research report is one of a series of new reports that provides gene therapy bioassays market statistics, including gene therapy bioassays industry global market size, regional shares, competitors with a gene therapy bioassays market share, detailed gene therapy bioassays market segments, market trends and opportunities, and any further data you may need to thrive in the gene therapy bioassays industry. This gene therapy bioassays market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene therapy bioassays are laboratory tests used to assess the biological activity, potency, and functional effectiveness of gene therapy products, ensuring that the therapeutic gene or vector operates as intended. They are crucial for evaluating gene expression, vector performance, and safety to support product development, quality assurance, and regulatory approval.

The primary product types of gene therapy bioassays include cell-based assays, viral vector-based assays, non-viral vector-based assays, and other product types. Cell-based assays utilize living cells to assess the efficacy, potency, and safety of gene therapy products under controlled laboratory conditions. These bioassays are offered as services including assay development, assay validation, quality control testing, regulatory support, data analysis and reporting, and custom bioassay design. They are applied in research and development, clinical testing, quality control, and other areas, and are used by biotechnology companies, pharmaceutical companies, contract research organizations, academic and research institutes, and regulatory laboratories.

The gene therapy bioassays market consists of sales of viral vector titer quantification reagents, reporter bioassay systems, nucleic acid purification systems, cell lines and assay-ready cells, and potency assay reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.